PULMATRIX, INC. Cash and Cash Equivalents, Period Increase (Decrease)
PULMATRIX, INC. (PULM) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$2.00 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-11
- PULMATRIX, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$2.00M, a 131.40% decline year-over-year.
- PULMATRIX, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$2.81M.
- PULMATRIX, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$4.62M.
- PULMATRIX, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $435.00K.
- PULMATRIX, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$632.00K.
- PULMATRIX, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$14.72M, a 179.78% decline from fiscal 2015.
- PULMATRIX, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $18.45M.
- PULMATRIX, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$974.00K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$2.00M 10-Q · filed 2018-05-11 | -$4.81M derived: sum of 2 quarters · filed 2018-05-11 | -$9.42M derived: sum of 3 quarters · filed 2018-05-11 | -$8.99M derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$7.43M derived: sum of 2 quarters · filed 2018-03-13 | -$6.99M derived: sum of 3 quarters · filed 2018-03-13 | -$632.00K 10-K · filed 2018-03-13 |
| 2017-09-30 | -$4.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$4.18M derived: sum of 2 quarters · filed 2017-11-09 | $2.18M 10-Q · filed 2017-11-09 | -$953.00K derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-06-30 | $435.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $6.79M 10-Q · filed 2017-08-04 | $3.66M derived: sum of 3 quarters · filed 2018-05-11 | $188.00K derived: sum of 4 quarters · filed 2018-05-11 |
| 2017-03-31 | $6.36M 10-Q · filed 2018-05-11 | $3.23M derived: sum of 2 quarters · filed 2018-05-11 | -$247.00K derived: sum of 3 quarters · filed 2018-05-11 | -$4.21M derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | -$3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$6.61M derived: sum of 2 quarters · filed 2018-03-13 | -$10.57M derived: sum of 3 quarters · filed 2018-03-13 | -$14.72M 10-K · filed 2018-03-13 |
| 2016-09-30 | -$3.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$7.44M derived: sum of 2 quarters · filed 2017-11-09 | -$11.59M 10-Q · filed 2017-11-09 | -$14.71M derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | -$3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | -$8.11M 10-Q · filed 2017-08-04 | -$11.24M derived: sum of 3 quarters · filed 2017-08-04 | -$14.72M derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-03-31 | -$4.15M 10-Q · filed 2017-05-05 | -$7.27M derived: sum of 2 quarters · filed 2017-05-05 | -$10.75M derived: sum of 3 quarters · filed 2017-05-05 | $12.01M derived: sum of 4 quarters · filed 2017-05-05 |
| 2015-12-31 | -$3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$6.61M derived: sum of 2 quarters · filed 2017-03-10 | $16.16M derived: sum of 3 quarters · filed 2017-03-10 | $18.45M 10-K · filed 2017-03-10 |
| 2015-09-30 | -$3.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $19.28M derived: sum of 2 quarters · filed 2016-11-04 | $21.57M 10-Q · filed 2016-11-04 | $21.27M derived: sum of 4 quarters · filed 2016-11-04 |
| 2015-06-30 | $22.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $25.06M 10-Q · filed 2016-08-04 | $24.75M derived: sum of 3 quarters · filed 2016-08-04 | $23.37M derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-03-31 | $2.29M 10-Q · filed 2016-05-05 | $1.99M derived: sum of 2 quarters · filed 2016-05-05 | $605.00K derived: sum of 3 quarters · filed 2016-05-05 | -$699.00K derived: sum of 4 quarters · filed 2016-05-05 |
| 2014-12-31 | -$302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | -$1.69M derived: sum of 2 quarters · filed 2016-03-10 | -$2.99M derived: sum of 3 quarters · filed 2016-03-10 | -$974.00K 10-K · filed 2016-03-10 |
| 2014-09-30 | -$1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-11-13 | -$2.69M 10-Q · filed 2014-11-13 | -$672.00K 10-Q · filed 2015-11-12 | |
| 2014-06-30 | -$1.30M 10-Q · filed 2014-08-14 | $81.00K 10-Q · filed 2015-08-14 | ||
| 2013-09-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-11-13 | -$7.00K 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | -$43.00K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |